Show simple item record

Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia

dc.contributor.authorMoos, Walter H.en_US
dc.contributor.authorManeta, Elenien_US
dc.contributor.authorPinkert, Carl A.en_US
dc.contributor.authorIrwin, Michael H.en_US
dc.contributor.authorHoffman, Michelle E.en_US
dc.contributor.authorFaller, Douglas V.en_US
dc.contributor.authorSteliou, Kostaen_US
dc.date.accessioned2020-05-14T17:19:00Z
dc.date.issued2016-03-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000374384000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e74115fe3da270499c3d65c9b17d654
dc.identifier.citationWalter H Moos, Eleni Maneta, Carl A Pinkert, Michael H Irwin, Michelle E Hoffman, Douglas V Faller, Kosta Steliou. 2016. "Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia." Drug Development Research Volume 77, Issue 2, pp. 53 - 72. https://doi.org/10.1002/ddr.21295
dc.identifier.issn0272-4391
dc.identifier.issn1098-2299
dc.identifier.urihttps://hdl.handle.net/2144/40859
dc.descriptionPlease note: this work is permanently embargoed in OpenBU. No public access is forecasted for this item. To request private access, please click on the locked Download file link and fill out the appropriate web form.en_US
dc.description.abstractNeuropsychiatric disorders are a heterogeneous group of conditions that often share underlying mitochondrial dysfunction and biological pathways implicated in their pathogenesis, progression, and treatment. To date, these disorders have proven notoriously resistant to molecular-targeted therapies, and clinical options are relegated to interventional types, which do not address the core symptoms of the disease. In this review, we discuss emerging epigenetic-driven approaches using novel acylcarnitine esters (carnitinoids) that act on master regulators of antioxidant and cytoprotective genes and mitophagic pathways. These carnitinoids are actively transported, mitochondria-localizing, biomimetic coenzyme A surrogates of short-chain fatty acids, which inhibit histone deacetylase and may reinvigorate synaptic plasticity and protect against neuronal damage. We outline these neuroprotective effects in the context of treatment of neuropsychiatric disorders such as autism spectrum disorder and schizophrenia.en_US
dc.description.sponsorshipWe thank the MitoCure Foundation for generous support of the underlying experimentation, PhenoMatriX for provision of small molecules, and both the US National Science Foundation and Auburn University for support of original research studies. We acknowledge efforts of Drs. Matthew V. Cannon, Kodeeswaran Parameshwaran, Vishnu Suppiramaniam, David N. Harpp, Edward G. Spack and Robert J. Zamboni, and the latter for his assistance with the chemical synthesis of PMX-500FI; and Drs. Susan P. Perrine, Michael S. Boosalis, and Jose Sangerman of the Boston University Cancer Research Center for their invaluable advice and helpful discussions in preparation of this manuscript. Conflict of interest: KS owns shares in PhenoMatriX. WM and KS have collaborated in the past on cancer projects as part of a formal agreement between SRI International and PhenoMatriX. The remaining authors declare no conflict of interest. (MitoCure Foundation; US National Science Foundation; Auburn University)en_US
dc.format.extentp. 53 - 72en_US
dc.languageEnglish
dc.language.isoen_US
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.relation.ispartofDrug Development Research
dc.subjectScience & technologyen_US
dc.subjectLife sciences & biomedicineen_US
dc.subjectChemistry, medicinalen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectAutismen_US
dc.subjectBipolaren_US
dc.subjectButyrateen_US
dc.subjectCarnitinoidsen_US
dc.subjectEpigeneticen_US
dc.subjectHistone deacetylaseen_US
dc.subjectNeurodegenerativeen_US
dc.subjectNeurodevelopmentalen_US
dc.subjectNeuropsychiatric disordersen_US
dc.subjectPMX-500en_US
dc.subjectParkinson diseaseen_US
dc.subjectSchizophreniaen_US
dc.subjectPMX-550en_US
dc.subjectHistone deacetylase inhibitorsen_US
dc.subjectAlpha-lipoic aciden_US
dc.subjectElectron-transport chainen_US
dc.subjectGene-environment interactionsen_US
dc.subjectNMDA receptor dysfunctionen_US
dc.subjectLong-term potentiationen_US
dc.subjectLamb rennet pasteen_US
dc.subjectSpectrum disordersen_US
dc.subjectNeurodevelopmental disordersen_US
dc.subjectAlzheimer diseaseen_US
dc.subjectMitochondrial dysfunctionen_US
dc.subjectAnimalsen_US
dc.subjectAutism spectrum disorderen_US
dc.subjectCarnitineen_US
dc.subjectEpigenomicsen_US
dc.subjectNeuroprotective agentsen_US
dc.subjectMitochondriaen_US
dc.subjectHumansen_US
dc.subjectAntioxidanten_US
dc.subjectPharmacology and pharmaceutical sciencesen_US
dc.titleEpigenetic treatment of neuropsychiatric disorders: autism and schizophreniaen_US
dc.typeArticleen_US
dc.description.versionAccepted manuscripten_US
dc.identifier.doi10.1002/ddr.21295
dc.description.embargo2031-01-01
pubs.elements-sourceweb-of-scienceen_US
pubs.notesOther: embargo indefinitelyen_US
pubs.organisational-groupBoston Universityen_US
pubs.organisational-groupBoston University, Administrationen_US
pubs.organisational-groupBoston University, School of Medicineen_US
pubs.publication-statusPublisheden_US
dc.identifier.orcid0000-0002-5530-3194 (Steliou, Kosta)
dc.identifier.mycv62168


This item appears in the following Collection(s)

Show simple item record